Sanuwave Health Stock News

SANUWAVE Health Inc. (OTCQB:SNWV) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Morgan Frank - Chairman and Chief Executive Officer Peter Sorensen - Chief Financial

Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company. Q2 2024 Gross Margin was 73%, vs 74% in Q2 2023 GAAP Operating Income was $2.0 Million Company Provides Guidance for Revenue Growth of 65-75% for Q3 2024 Versus Q3 2023 EDEN PRAIRIE, MN -- August 13, 2024 -- InvestorsHub NewsWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-app...

Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company.

SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results EDEN PRAIRIE, MN -- August 8, 2024 -- InvestorsHub NewsWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Tuesday, August 13, 2024, at 8:30 AM (ET) to present the Q2 2024 financial results. Telephone access to the call will be available...

EDEN PRAIRIE, MN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will ho

SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history.

Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE

SANUWAVE Health Inc. (SNWV) Q4 2023 Earnings Call Transcript

Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating l

EDEN PRAIRIE, MN, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound

At a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 “for” and 5,221,765 “agains

EDEN PRAIRIE, MN, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved woun

SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company.

EDEN PRAIRIE, MN,, Nov. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved

EDEN PRAIRIE, MN, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call